BimEL-CST-2A (R186A-R190A)

General Information


DRACP ID  DRACP03046

Peptide Name   BimEL-CST-2A (R186A-R190A)

Sequence  PQMVILQLLAFIFALVWRRH

Sequence Length  20

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Cancer targeted peptides Induce apoptosis Bcl-xL/Bac-2 inhibitors BH3 peptides and mimetics



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Bcl-2/Bcl-xL

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP03046

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C119H187N31O23S

Absent amino acids  CDEGKNSTY

Common amino acids  L

Mass  279115

Pl  12.5

Basic residues  3

Acidic residues  0

Hydrophobic residues  13

Net charge  3

Boman Index  628

Hydrophobicity  110

Aliphatic Index  156

Half Life 
  Mammalian: >20 hour
  Yeast: >20 hour
  E.coli: ?

Extinction Coefficient cystines  5500

Absorbance 280nm  289.47

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 30860026

Title  Bim escapes displacement by BH3-mimetic anti-cancer drugs by double-bolt locking both Bcl-XL and Bcl-2

Doi 10.7554/eLife.37689

Year  2019

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.